Cargando…

Risk of Candida Infection and Serious Infections in Patients with Moderate-to-Severe Psoriasis Receiving Biologics: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

BACKGROUND: Biological agents used to treat moderate-to-severe plaque psoriasis have been associated with Candida infection and other serious infections. It is, however, necessary to verify whether biologic agents increase the risk of Candida infection and serious infections and whether these risks...

Descripción completa

Detalles Bibliográficos
Autores principales:	Feng, Yue, Zhou, Baosen, Wang, Zhen, Xu, Guijuan, Wang, Lili, Zhang, Tingting, Zhang, Yanping
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi 2022
Materias:	Review Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9519312/ https://www.ncbi.nlm.nih.gov/pubmed/36212052 http://dx.doi.org/10.1155/2022/2442603

Ejemplares similares

Infections in Patients Receiving Subcutaneous Biological Treatments for Moderate to Severe Psoriasis
por: Messori, Andrea, et al.
Publicado: (2015)

Risk of Serious Infection in Patients with Psoriasis Receiving Biologic Therapies: A Prospective Cohort Study from the British Association of Dermatologists Biologic Interventions Register (BADBIR)
por: Yiu, Zenas Z.N., et al.
Publicado: (2018)

Seven cancer patients receiving guselkumab for treatment of moderate-to-severe psoriasis
por: Mastorino, Luca, et al.
Publicado: (2022)

Development and validation of a multivariable risk prediction model for serious infection in patients with psoriasis receiving systemic therapy
por: Yiu, Z.Z.N., et al.
Publicado: (2019)

Biological therapies in moderate and severe psoriasis: perspectives and certainties
por: Constantin, MM, et al.
Publicado: (2014)

THE MANAGEMENT OF MODERATE TO SEVERE PSORIASIS: A BIOLOGIC REVOLUTION
por: Skillen, LA, et al.
Publicado: (2018)

Biologic and Small-Molecule Therapies for Moderate-to-Severe Psoriasis: Focus on Psoriasis Comorbidities
por: Jiang, Yuxiong, et al.
Publicado: (2023)

Risk of Serious Infections in Patients with Psoriasis on Biologic Therapies: A Systematic Review and Meta-Analysis
por: Yiu, Zenas Z.N., et al.
Publicado: (2016)

Understanding efficacy-safety balance of biologics in moderate-to-severe pediatric psoriasis
por: Golhen, Klervi, et al.
Publicado: (2022)

Influence of Genetic Polymorphisms on Response to Biologics in Moderate-to-Severe Psoriasis
por: Membrive Jiménez, Cristina, et al.
Publicado: (2021)

Efficacy of several biological therapies for treating moderate to severe psoriasis: A network meta-analysis
por: Geng, Wenjun, et al.
Publicado: (2018)

Bounded integer model‐based analysis of psoriasis area and severity index in patients with moderate‐to‐severe plaque psoriasis receiving BI 730357
por: Ooi, Qing Xi, et al.
Publicado: (2023)

Therapy of moderate and severe psoriasis
por: Claes, Christa, et al.
Publicado: (2006)

Moderate to severe psoriasis treatment challenges through the era of biological drugs
por: Vide, Júlia, et al.
Publicado: (2017)

Health Economic Assessment of Optimal Biological Treatment for Moderate-to-Severe Psoriasis
por: Barker, Jonathan, et al.
Publicado: (2021)

Management Strategies for Pediatric Moderate-to-Severe Plaque Psoriasis: Spotlight on Biologics
por: Ruggiero, Angelo, et al.
Publicado: (2023)

Comparative short-term risks of infection and serious infection in patients receiving biologic and small-molecule therapies for psoriasis and psoriatic arthritis: a systemic review and network meta-analysis of randomized controlled trials
por: Chiu, Hsien-Yi, et al.
Publicado: (2023)

Risk of serious infection among patients receiving biologics for chronic inflammatory diseases: Usefulness of administrative data
por: Quartuccio, Luca, et al.
Publicado: (2018)

Serious infections in patients with self-reported psoriatic arthritis from the Psoriasis Longitudinal Assessment and Registry (PSOLAR) treated with biologics
por: Ritchlin, Christopher T., et al.
Publicado: (2019)

The Risk of COVID-19 Pandemic in Patients with Moderate to Severe Plaque Psoriasis Receiving Systemic Treatments
por: Gisondi, Paolo, et al.
Publicado: (2020)

A New Classification of the Severity of Psoriasis: What’s Moderate Psoriasis?
por: Salgado-Boquete, Laura, et al.
Publicado: (2021)

Treatment Approaches to Moderate to Severe Psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2017)

Clinical, dermoscopic, and ultrasonic monitoring of the response to biologic treatment in patients with moderate-to-severe plaque psoriasis
por: Wang, Juncheng, et al.
Publicado: (2023)

Number Needed to Treat Network Meta-Analysis to Compare Biologic Drugs for Moderate-to-Severe Psoriasis
por: Leonardi, Craig L., et al.
Publicado: (2022)

Impact of Functional Polymorphisms on Drug Survival of Biological Therapies in Patients with Moderate-to-Severe Psoriasis
por: Membrive-Jiménez, Cristina, et al.
Publicado: (2023)

Treatment outcomes with ixekizumab in patients with moderate‐to‐severe psoriasis who have or have not received prior biological therapies: an integrated analysis of two Phase III randomized studies
por: Gottlieb, A.B., et al.
Publicado: (2016)

Patient-reported treatment satisfaction and choice of dosing frequency with biologic treatment for moderate to severe plaque psoriasis
por: Zhang, Mingliang, et al.
Publicado: (2015)

Annual biologic treatment cost for new and existing patients with moderate to severe plaque psoriasis in Greece
por: Fragoulakis, Vassilis, et al.
Publicado: (2015)

Subcutaneous Biological Treatments for Moderate to Severe Psoriasis: Interpreting Safety Data by Network Meta-Analysis
por: Messori, Andrea, et al.
Publicado: (2015)

Biologic Treatment Algorithms for Moderate-to-Severe Psoriasis with Comorbid Conditions and Special Populations: A Review
por: Thatiparthi, Akshitha, et al.
Publicado: (2021)

Predictors of Response to Biologics in Patients with Moderate-to-severe Psoriasis: A Danish Nationwide Cohort Study
por: SCHWARZ, Christopher Willy, et al.
Publicado: (2021)

Switches between biologics in patients with moderate‐to‐severe psoriasis: results from the French cohort PSOBIOTEQ
por: Curmin, R., et al.
Publicado: (2022)

Which Areas Are Still Left in Biologics Responsive Korean Patients with Moderate to Severe Plaque Psoriasis
por: Won, Sang-Hyeon, et al.
Publicado: (2023)

Apremilast Pharmacogenomics in Russian Patients with Moderate-to-Severe and Severe Psoriasis
por: Verbenko, Dmitry A., et al.
Publicado: (2020)

Evaluating Potential Disease‐Mediated Protein‐Drug Interactions in Patients With Moderate‐to‐Severe Plaque Psoriasis Receiving Subcutaneous Guselkumab
por: Zhu, Yaowei, et al.
Publicado: (2020)

Activated Circulating T Follicular Helper Cells Are Associated with Disease Severity in Patients with Psoriasis
por: Wang, Ying, et al.
Publicado: (2016)

Rates of Serious Intracellular Infections in Autoimmune Disease Patients Receiving Initial Glucocorticoid Therapy
por: Migita, Kiyoshi, et al.
Publicado: (2013)

Drug focus: adalimumab in the treatment of moderate to severe psoriasis
por: Vena, Gino A, et al.
Publicado: (2007)

Management of Moderate to Severe Psoriasis in Patients with Metabolic Comorbidities
por: Gisondi, Paolo, et al.
Publicado: (2015)

Apremilast in the therapy of moderate-to-severe chronic plaque psoriasis
por: Gisondi, Paolo, et al.
Publicado: (2016)

Cannot write session to /tmp/vufind_sessions/sess_b5e892smj0dvvnkrq0u1ub23em